Christina Messiou1, David J. Collins1, Sharon Giles1, Veronica A. Morgan1, Johann S. de Bono2, Diletta Bianchini2, Nandita M. deSouza1
1CRUK & EPSRC Cancer Imaging Centre, Institute of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 2Medicine, Institute of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
The purpose of this study was to determine whether changes in ADC in patients with metastatic bone disease secondary to carcinoma of the prostate are significantly different in responders compared to progressors following chemotherapy. The results demonstrate that both ADC and ADCslow increase significantly in responders and progressors. No significant change in ADC in stable patients agreed fully with PSA/RECIST criteria of stable disease. The application of thresholds to ADC histogram analysis to identify proportions of normal and diseased marrow may be a better indicator of response or progression and allow wider separation of responding and progressing patients.